73.82 <%= Resources.Global.txtUp %>
Updated 15/10/2018
Change % 0.35% Stock price increasing
Change 0.26 Stock price increasing
Volume 271,406
High 74.00
Low 72.88
Open 73.46
ISIN BE0003739530
Prev close 73.56
# of shares 194.51M
Market cap 14,358M EUR

Market closed
Market is closed, opens at 08:00
Price development Latest 1 week 1 month 3 months 6 months 1 year
  73.82 -3.9% Stock price decreasing -7.7% Stock price decreasing 4.9% Stock price increasing 13.0% Stock price increasing 23.2% Stock price increasing
Powered by TradingView

Company profile

UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, both of which have lost patent protection. The firm's newer key drugs include Cimzia (rheumatoid arthritis, psoriatic arthritis, and Crohn's disease), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), and Briviact (epilepsy).

Copyright Berlingske Media 2018  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
16 October 2018 01:08:06
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20181005.3 - EUROWEB6 - 2018-10-16 02:08:06 - 2018-10-16 01:08:06 - 1000 - Website: OKAY